PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20144270-7	2010	RESULTS: Lymphocytes from patients with IgAN secreted more IgA1 than that from normal controls after LPS stimulation (P=0.26, 0.002 and 0.005 on the 3rd, 5th and 7th day, respectively) which could be inhibited by 5-AZA (P=0.001, 0.025 and 0.001 on the 3rd, 5th and 7th day, respectively).	Azacitidine	213-218	immunoglobulin heavy constant alpha 1	Homo sapiens	59-63	
20144270-9	2010	When 5-AZA was added, the level of C1GALT1C1 expression increased dramatically (1.98, 5.53 and 8.97 times on the 3rd, 5th and 7th day, respectively; P < 0.001) along with an increase of IgA1 O-glycosylation (P=0.295, 0.09 and 0.003 on the 3rd, 5th and 7th day, respectively).	Azacitidine	5-10	immunoglobulin heavy constant alpha 1	Homo sapiens	189-193	
20144270-12	2010	Upregulation of C1GALT1C1 expression by 5-AZA could reverse the IgA1 aberrant O-glycosylation.	Azacitidine	40-45	immunoglobulin heavy constant alpha 1	Homo sapiens	64-68	
29299950-12	2018	The molecular mechanism for the IgA1 underglycosylation induced by IL-17 was similar to that of LPS; however, 5-AZA inhibited IgA1 underglycosylation.	Azacitidine	110-115	immunoglobulin heavy constant alpha 1	Homo sapiens	32-36	
29299950-12	2018	The molecular mechanism for the IgA1 underglycosylation induced by IL-17 was similar to that of LPS; however, 5-AZA inhibited IgA1 underglycosylation.	Azacitidine	110-115	immunoglobulin heavy constant alpha 1	Homo sapiens	126-130